Literature DB >> 1774442

Oxytocin does not modify the prolactin response to metoclopramide in normal women.

P Chiodera1, R Volpi, D Gramellini, C Cigarini, A Corradi, U Cavazzini, L Bianconi, C Papadia, A Caiazza, L Capretti.   

Abstract

The present study was undertaken in order to establish whether oxytocin (OT) affects the dopaminergic control of PRL secretion in normal women during follicular, periovulatory and luteal phase of their menstrual cycle. For this purpose, 22 normal women were tested with a lower (1 mg) or higher (10 mg) dose of the dopaminergic antagonist metoclopramide (MCP) with or without the concurrent treatment with OT (2 IU injected plus 0.033 IU/min infused for 2 h). Since OT was found unable to modify the effect of either 1 or 10 mg MCP, in additional experiments the same doses of MCP and OT were administered after dopamine (0.04 micrograms/kg/min for 2 h) infusion. Also in these experimental conditions OT failed to modify the PRL response to MCP. These data argue against a role of OT in modulation of the dopaminergic control of PRL secretion in normal women.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1774442     DOI: 10.1007/BF03346844

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  25 in total

1.  Oxytocin enhances thyrotropin-releasing hormone-induced prolactin release in normal menstruating women.

Authors:  V Coiro; A Gnudi; R Volpi; C Marchesi; G Salati; P Caffarra; P Chiodera
Journal:  Fertil Steril       Date:  1987-04       Impact factor: 7.329

Review 2.  Mechanism of thyrotropin releasing hormone stimulation of pituitary hormone secretion.

Authors:  M C Gershengorn
Journal:  Annu Rev Physiol       Date:  1986       Impact factor: 19.318

3.  Role of oxytocin on prolactin secretion during proestrus and in different physiological or pharmacological paradigms.

Authors:  C A Johnston; A Negro-Vilar
Journal:  Endocrinology       Date:  1988-01       Impact factor: 4.736

4.  Increased responsiveness of the dopamine-mediated inhibition of prolactin synthesis after destruction of the medial basal hypothalamus.

Authors:  C Y Cheung; R W Kuhn; R I Weiner
Journal:  Endocrinology       Date:  1981-03       Impact factor: 4.736

5.  High concentrations of oxytocin in hypophysial portal plasma.

Authors:  D M Gibbs
Journal:  Endocrinology       Date:  1984-04       Impact factor: 4.736

Review 6.  Posterior pituitary function in health and disease.

Authors:  P H Baylis
Journal:  Clin Endocrinol Metab       Date:  1983-11

7.  Identification of the vasopressin producing and of the oxytocin producing neurons in the hypothalamic magnocellular neurosecretroy system of the rat.

Authors:  F Vandesande; K Dierickx
Journal:  Cell Tissue Res       Date:  1975-12-02       Impact factor: 5.249

8.  Regulation of prolactin secretion by dopamine and thyrotropin-releasing hormone in lactating rat adenohypophyses: influence of intracellular age of the hormone.

Authors:  F Mena; C Clapp; D Aguayo; M T Morales; C E Grosvenor; G Martínez de la Escalera
Journal:  Endocrinology       Date:  1989-10       Impact factor: 4.736

9.  Effect of metroclopramide on serum prolactin levels in humans.

Authors:  G Delitala; A Masala; S Alagna; L Devilla
Journal:  Clin Endocrinol (Oxf)       Date:  1976-11       Impact factor: 3.478

10.  The effect of oxytocin infusion on adenohypophyseal function in man.

Authors:  S R Page; V T Ang; R Jackson; A White; S S Nussey; J S Jenkins
Journal:  Clin Endocrinol (Oxf)       Date:  1990-03       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.